Optimizing Drug Therapies in Patients with COPD in the US Nursing Home Setting
- 34 Downloads
Chronic obstructive pulmonary disease (COPD) can be a disabling disease, and the impact on older adults is particularly evident in the nursing home setting. Chronic obstructive pulmonary disease is present in about 20% of nursing home residents, most often in women, and accounts for significant healthcare utilization including acute care visits for exacerbations and pneumonia, as well as worsening heart disease and diabetes mellitus. The emphasis on hospital readmissions is particularly important in nursing homes where institutions have quality measures that have financial implications. Optimizing drug therapies in individuals with COPD involves choosing medications that not only improve symptoms, but also decrease the risk of exacerbations. Optimizing the treatment of comorbidities such as heart disease, infections, and diabetes that may affect COPD outcomes is also an important consideration. Depending on the nursing home setting and the patient, the options for optimizing COPD drug therapies may be limited owing to patient-related factors such as cognition and physical impairment or available resources, primarily reimbursement-related issues. Choosing the best drug therapy for COPD in older adults is limited by the difficulty in assessing respiratory symptoms using standardized assessment tools and potentially decreased inspiratory ability of frail individuals. Because of cognitive and physical impediments, ensuring optimal delivery of inhaled medications into the lungs has significant challenges. Long-acting bronchodilators, inhaled corticosteroids, and roflumilast decrease the risk of exacerbations, although inhaled corticosteroids should be used judiciously in this population because of the risk of pneumonia and oropharyngeal side effects. Treatment of COPD exacerbations should occur early and consideration should be made to the benefits and risks of systemic corticosteroids and antibiotics. Clinical research in the COPD population in nursing homes is clearly lacking, and ripe for discovery of effective management strategies.
Compliance with Ethical Standards
No funding was received for the preparation of this manuscript.
Conflict of Interest
Roy A. Pleasants has disclosures for Sunovion, Teva, Boehringer Ingelheim, GlaxoSmithKline, and Grifols. Peter A. Radlowski and H. Edward Davidson have received research grant support from Sunovion Pharmaceuticals.
- 2.Harris-Kojetin L, Sengupta M, Park-Lee E, Valverde R, Caffrey C, Rome V, et al. Long-term care providers and services users in the United States: data from the National Study of Long-Term Care Providers, 2013–2014. Vital Health Stat. 2016;3(3):1–105.Google Scholar
- 3.Centers for Medicare and Medicaid Services. MDS 3.0 frequency report: second quarter 2018. 2018. https://www.cms.gov/Research-Statistics-Data-and-Systems/Computer-Data-and-Systems/Minimum-Data-Set-3-0-Public-Reports/Minimum-Data-Set-3-0-Frequency-Report.html. Accessed 24 Aug 2018.
- 5.Centers for Medicare and Medicaid Services. Hospital Readmission Reduction Program (HRRP). 2018. https://www.cms.gov/medicare/medicare-fee-for-service-payment/acuteinpatientpps/readmissions-reduction-program.html. Accessed 1 Dec 2018.
- 7.Pleasants RA, Herrick H, Liao W. The prevalence, characteristics, and impact of chronic obstructive pulmonary disease in North Carolina. N C Med J. 2013;74:376–83.Google Scholar
- 9.Zarowitz BJ, O’Shea T. Chronic obstructive pulmonary disease: prevalence, characteristics, and pharmacologic treatment in nursing home residents with cognitive impairment. J Manag Care Pharm. 2012;18:598–606.Google Scholar
- 10.Gravenstein S, Davidson HE, Taljaard M, Ogarek J, Gozalo P, Han L, et al. Comparative effectiveness of high-dose versus standard-dose influenza vaccination on numbers of US nursing home residents admitted to hospital: a cluster-randomised trial. Lancet Respir Med. 2017;5:738–46.CrossRefGoogle Scholar
- 16.Campbell EJ, Lefrak SS. How aging affects the structure and function of the respiratory system. Geriatrics. 1978;33:68–74.Google Scholar
- 17.Kojima G, Iliffe S, Taniguchi Y, Shimada H, Rakugi H, Walters K. Prevalence of frailty in Japan: a systematic review and meta-analysis. J Epidemiol. 2017;16:940–5.Google Scholar
- 21.Phu S, Vogrin S, Zanker J, Bani Hassan E, Al Saedi A, Duque G. Agreement between initial and revised European Working Group on Sarcopenia in older people definitions. J Am Med Dir Assoc. 2019;20(382–383):e1.Google Scholar
- 23.Vanfleteren LEGW, Spruit MA, Groenen M, Gaffron S, Van Empel VPM, Bruijnzeel PLB, et al. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;187:728–35.CrossRefGoogle Scholar
- 24.Urzi F, Šimunič B, Buzan E. Basis for sarcopenia screening with the SARC-CalF in nursing homes. J Am Med Dir Assoc. 2017;18(e5–991):e10.Google Scholar
- 34.Global Inititiative For Chronic Obstructive Lung Disease. Gold 2019. https://goldcopd.org/wp-content/uploads/2018/11/GOLD-2019-v1.7-FINAL-14Nov2018-WMS.pdf. Accessed 25 Mar 2019.
- 37.Pathway Health. Interventions to reduce acute care transfers. Lake Elmo: Pathway Health; 2018. http://www.pathway-interact.com. Accessed 11 Jan 2019.
- 38.American Medical Directors Association. Transitions of care in the long-term care continuum clinical practice guideline. Columbia (MD): The American Medical Directors Association; 2010.Google Scholar
- 57.Walters JA, Tang JN, Poole P, Wood-Baker R. Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2017;1:CD001390.Google Scholar
- 63.Parissis JT, Andreoli C, Kadoglou N, Ikonomidis I, Farmakis D, Dimopoulou I, et al. Differences in clinical characteristics, management and short-term outcome between acute heart failure patients chronic obstructive pulmonary disease and those without this co-morbidity. Clin Res Cardiol. 2014;103:733–41.CrossRefGoogle Scholar
- 64.Stefan MS, Rothberg MB, Priya A, Pekow PS, Au DH, Lindenauer PK. Association between β-blocker therapy and outcomes in patients hospitalised with acute exacerbations of chronic obstructive lung disease with underlying ischaemic heart disease, heart failure or hypertension. Thorax. 2012;67:977–84.CrossRefGoogle Scholar
- 67.Du Q, Sun Y, Ding N, Lu L, Chen Y. Beta-blockers reduced the risk of mortality and exacerbation in patients with COPD: a meta-analysis of observational studies. PLoS One. 2014;9:1130–48.Google Scholar
- 70.Tivenius L. Effects of muliple doses of metoprolol and propranolol on ventilatory function in patients with chronic obstructive lung disease. Scand J Respir Dis. 1976;57:190–6.Google Scholar
- 71.Dransfield MT, McAllister DA, Anderson JA, Brook RD, Calverley PMA, Celli BR, et al. β-Blocker therapy and clinical outcomes in patients with moderate chronic obstructive pulmonary disease and heightened cardiovascular risk: an observational substudy of SUMMIT. Ann Am Thorac Soc. 2018;15:608–14.CrossRefGoogle Scholar
- 74.Boehringer Ingelheim Pharmaceuticals I. STRIVERDI (olodaterol). Ridgefield (CT): Boehringer Ingelheim Pharmaceuticals, Inc.; 2014. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/203108s000lbl.pdf. Accessed 1 Dec 2018.
- 75.GlaxoSmithKline. Serevent (salmeterol xinafoate) inhalation aerosol. 2003: p. 1–23. https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Serevent_Diskus/pdf/SEREVENT-DISKUS-PI-MG-IFU.PDF. Accessed 1 Dec 2018.
- 76.Merck. Foradil packing insert. Whitehouse Station (NJ): Merck & Co., Inc.; 2012. https://www.merck.com/product/usa/pi_circulars/f/foradil/foradil_pi.pdf. Accessed 1 Dec 2018.
- 77.Pharmaceutics S. Arcapta (indacaterol inhalation powder). Marlborough (MA): Sunovion Pharmaceuticals; 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label//022383s000lbl.pdf. Accessed 1 Dec 2018.
- 78.GlaxoSmithKline/Theravance. England and Whale UK. ANORO ELLIPTA (umeclidinium and vilanterol inhalation powder). Research Triangle Park (NC): GlaxoSmithKline; 2013. pp. 1–35. https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Anoro_Ellipta/pdf/ANORO-ELLIPTA-PI-MG.PDF. Accessed 1 Dec 2018.